

Andrew Ip

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7399190/andrew-ip-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

452
citations

8
h-index

21
g-index

28
ext. papers

602
ext. citations

4.2
avg, IF

3.29
L-index

#	Paper	IF	Citations
22	Clotting events among hospitalized patients infected with COVID-19 in a large multisite cohort in the United States.. <i>PLoS ONE</i> , 2022 , 17, e0262352	3.7	0
21	Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation.. <i>JAMA Network Open</i> , 2022 , 5, e223687	10.4	0
20	Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Blood</i> , 2021 , 138, 165-165	2.2	0
19	A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy. <i>Blood</i> , 2021 , 138, 2495-2495	2.2	0
18	COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2021 , 16, e0248128	3.7	4
17	Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. <i>JCI Insight</i> , 2021 , 6,	9.9	17
16	Late immune-related adverse events with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2635-2635	2.2	
15	Real-world outcomes of treatment with immune checkpoint inhibitors in unique patient cohorts: Elderly, non-caucasian race, poor performance status, obese, chronic viral infections, and autoimmune diseases.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2641-2641	2.2	
14	Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19. <i>PLoS ONE</i> , 2021 , 16, e0255228	3.7	1
13	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. <i>BMC Infectious Diseases</i> , 2021 , 21, 72	4	19
12	Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1367-1368	2.2	4
11	Higher Incidence of Germline Mutations in DNA Damage Response Genes in Lymphoid Than in Myeloid Neoplasms without Significant Increase in the Prevalence of Clonal Hematopoiesis. <i>Blood</i> , 2020 , 136, 4-5	2.2	
10	COVID-19 Impact on Lymphoma PatientsaClinical Outcomes - an Observational Cohort Study. <i>Blood</i> , 2020 , 136, 6-7	2.2	3
9	Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. <i>PLoS ONE</i> , 2020 , 15, e0237693	3.7	84
8	Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e603-e612	14.2	173
7	Induction Therapy in Localized Pancreatic Cancer. <i>Pancreas</i> , 2019 , 48, 913-919	2.6	3
6	Clinical Integration of Digital Solutions in Health Care: An Overview of the Current Landscape of Digital Technologies in Cancer Care. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-9	5.2	49

5	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018 , 93, 1543-1550	7.1	8
4	Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. <i>Oncologist</i> , 2016 , 21, 178-87	5.7	38
3	Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19		21
2	Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients [An Observational Study]		20
1	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study		7